Theravance Biopharma reaffirms FY24 R&D expenses view $30M-$36M
PremiumThe FlyTheravance Biopharma reaffirms FY24 R&D expenses view $30M-$36M
2M ago
Theravance Biopharma reports Q2 EPS (34c) with items, consensus (21c)
Premium
The Fly
Theravance Biopharma reports Q2 EPS (34c) with items, consensus (21c)
2M ago
TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
Theravance Biopharma reports Q1 EPS (24c), consensus (25c)
PremiumThe FlyTheravance Biopharma reports Q1 EPS (24c), consensus (25c)
4M ago
Is TBPH a Buy, Before Earnings?
Premium
Pre-Earnings
Is TBPH a Buy, Before Earnings?
4M ago
Fly Insider: Theravance Bio, Amgen among week’s notable insider trades
Premium
The Fly
Fly Insider: Theravance Bio, Amgen among week’s notable insider trades
5M ago
TBPH Earnings this Week: How Will it Perform?
PremiumPre-EarningsTBPH Earnings this Week: How Will it Perform?
7M ago
Theravance Biopharma downgraded at Evercore ISI after Yupelri trial failure
Premium
The Fly
Theravance Biopharma downgraded at Evercore ISI after Yupelri trial failure
9M ago
Theravance Biopharma downgraded to In Line from Outperform at Evercore ISI
Premium
The Fly
Theravance Biopharma downgraded to In Line from Outperform at Evercore ISI
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100